FDA Approves Diroximel Fumarate for Relapsing Forms of Multiple Sclerosis
October 30th 2019Patients in a phase 3 study reported better gastrointestinal tolerability with diroximel fumarate (Vumerity) compared with dimethyl fumarate (Tecfidera) in patients with relapsing forms of multiple sclerosis.
Read More
New Legislation for Drug Shortages Praised by Health Care Groups
October 30th 2019Multiple health care organizations, including The American Hospital Association (AHA), the Institute for Safe Medication Practices (ISMP), and the American Society of Health-System Pharmacists (ASHP), have shown their full support for the MEDS Act.
Read More
Cellular Respiration Significantly Increases in Patients with Primary Immunodeficiency Disorders
October 28th 2019Metabolic activity in the immune cells of patients with primary immunodeficiency was used as a biomarker due to cellular metabolism, which serves as a key regulator in immune cells.
Read More
2019 Next-Generation Pharmacist® Winners are Announced
October 28th 2019Pharmacy Times® and Parata Systems, the founding partners of the Next-Generation Pharmacist® awards, honored the 2019 winners, named at the annual awards gala Friday, October 25, at the Hotel del Coronado in San Diego, California.
Read More
Alprazolam Tablets Recalled for Foreign Substance
October 26th 2019Mylan Pharmaceuticals Inc. is operating a voluntary nationwide recall of one lot of Alprazolam Tablets, USP C-IV 0.5 mg to the consumer/user level. This recall stems from the potential presence of foreign substance, and to date, Mylan has not received any adverse events related to this batch.
Read More
New Treatment for CABP Receives FDA Approval
October 25th 2019Officials with the FDA have expanded the use of Melinta Therapeutics’ delafloxacin (Baxdela) to include treatment of adult patients with community-acquired bacterial pneumonia caused by designated susceptible bacteria, but the drug’s availability will be delayed for this new indication.
Read More
Bedtime Hypertension Treatment More Effective Than Morning Treatment
October 25th 2019Researchers have found that patients with high blood pressure (BP) who take all their antihypertensive medications at bedtime have better controlled blood pressure and a significantly lower risk of death or illness caused by heart or blood vessel problems, compared to patients who take their medications in the morning.1
Read More
Combination Therapy Shown to Increase Overall Survival and Progression-free Survival for HCC
October 24th 2019Genentech has announced the results of a Phase III study which showed that atezolizumab (Tecentriq) in combination with bevacizumab (Avastin) increased overall survival and progression-free survival in patients with unresectable hepatocellular carcinoma (HCC).
Read More
FDA Approves Therapy for Children with Lower Limb Spasticity
October 24th 2019Officials with the FDA have approved Allergan’s supplemental Biologics License Application (sBLA) for onabotulinumtoxinA (BOTOX®) to expand its indication to include treatment of pediatric patients, ages 2 to 17 years, with lower limb spasticity, excluding spasticity caused by cerebral palsy.
Read More